CD91:F:F-Lyxor NYSE Arca Gold BUGS (DR) UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 26.18

Change

-0.12 (-0.44)%

Market Cap

USD 0.31B

Volume

1.42K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

N/A

USD 116.19B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 109.51B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

-0.25 (-0.44%)

USD 98.97B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.04 (-0.27%)

USD 63.27B
SXRZ:F iShares VII PLC - iShares Nikk..

-0.45 (-0.19%)

USD 52.42B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.41 (+0.38%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

-0.06 (-0.85%)

USD 38.52B
0ZC:F Zscaler Inc

+7.40 (+4.31%)

USD 37.92B

ETFs Containing CD91:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 19.57% 75% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.57% 72% C 62% D
Trailing 12 Months  
Capital Gain 19.57% 74% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.57% 71% C- 61% D-
Trailing 5 Years  
Capital Gain 29.70% 62% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 29.70% 61% D- 46% F
Average Annual (5 Year Horizon)  
Capital Gain 1.92% 41% F 47% F
Dividend Return 1.92% 38% F 41% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 17.62% 30% F 73% C
Risk Adjusted Return 10.91% 34% F 42% F
Market Capitalization 0.31B 52% F 43% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.